Modern Concepts of Acute and Chronic Hepatitis


Book Description

The literature of medicine continues to expand at a remarkable pace. The number of papers and monographs published has increased dramatically in the past five years. Nowhere has this increase been as dramatic as in the field of acute and chronic hepatitis. Why then should there be still another book? Despite the sheer volume of words published, it is still difficult to find in anyone volume a compilation of all of the most significant work. Most mono graphs have considered either chronic or acute hepatitis, not both. Few works have addressed both the clinician and the basic scientist. This book addresses both of these audiences and considers both of these diseases. It was designed to provide an authoritative but concise assessment of our changing concepts of acute and chronic hepatitis. It covers what is currently known and, based on the most convincing research, believed about these diseases. To fulfill this ambitious goal, only authors with international reputations in their fields of expertise were invited to contribute. In the evolution of our current thoughts on the pathogenesis and manage ment of acute and chronic hepatitis, our ideas have changed several times. This book presents the facts as they are known today and, in areas where all the facts are not established, presents the well-founded opinions of those considered to be authorities. The authors present established and usually confirmed data and do not deal extensively with areas of speculation or unconfirmed material.







Chronic Liver Failure


Book Description

Chronic liver failure is a frequent condition in clinical practice that encompasses all manifestations of patients with end-stage liver diseases. Chronic liver failure is a multiorgan syndrome that affects the liver, kidneys, brain, heart, lungs, adrenal glands, and vascular, coagulation, and immune systems. Chronic Liver Failure: Mechanisms and Management covers for the first time all aspects of chronic liver failure in a single book, from pathogenesis to current management. Each chapter is written by a worldwide known expert in their area and all provide the latest state-of-the-art knowledge. This volume is specifically designed to provide answers to clinical questions to all doctors dealing with patients with liver diseases, not only clinical gastroenterologists and hepatologists, but also to internists, nephrologists, intensive care physicians, and transplant surgeons.




Understanding Hepatitis


Book Description

Hepatitis, or inflammation of the liver, has many causes, including several viruses, a host of chemicals and drugs, bacteria, diseases of the immune system, inherited factors, and herbs. For most of the population hepatitis refers to a disease caused by viruses, and viral hepatitis is the major concern of this book. However many of the nonviral types also are mentioned. Every year, about 140,000 new cases of hepatitis A occur in the United States, and perhaps over a million around the world. Because some who are infected do not become ill, the statistics are perhaps ten times greater than the number recognized. Fortunately, this strain is not chronic (defined as disease that lasts longer than six months). Hepatitis B infects about 1,250,000 in the U.S. and about 350,000,000 worldwide. Hepatitis C, unique in many ways and virtually always chronic, has produced some 4,000,000 cases in the U.S. About 1.6 percent of the population has been infected at some time, and at least seventy-five percent in this group retain the live virus in their blood. A fourth virus, hepatitis D, is uncommon in the United States. Because viral hepatitis sometimes has serious acute and chronic consequences, reference to it often tends to raise unreasonable fears of death or disability. However, the majority who become infected suffer few complications or long-term effects. The infection rate has decreased dramatically in recent years. In comprehensible terms Understanding Hepatitis furnishes the reader with a better grasp of the disease. Featured in this book are a historical overview, a discussion of symptoms and treatment, and a report on current research. This information not only debunks fearful myths but also provides helpful particulars on how to avoid the risks for contracting hepatitis. James L. Achord, a professor emeritus at the University of Mississippi Medical Center, has published articles in such publications as Conn's Current Therapy, Gastroenterology and Hepatology: Pearls of Wisdom, and Clinical Medicine .




Guidelines on Hepatitis B and C Testing


Book Description

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.




Hepatitis and Liver Cancer


Book Description

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.




Viral Hepatitis


Book Description

The 4th edition of Viral Hepatitis covers comprehensively the entire complex field of infections caused by all of the different hepatitis viruses, which affect many millions of people throughout the world with considerable morbidity and mortality. Howard Thomas and Arie Zuckerman are joined by Anna Lok from the USA and Stephen Locarnini from Australia as Editors. They have recruited leading researchers and physicians from many countries, who have produced an authoritative account of current knowledge and research on this important infection, including new insights into immune response to HBV and HCV. The result is a comprehensive account on all aspects of viral hepatitis, including rapid advances in the diagnosis, management, treatment and prevention of a complex infection, which in the case of hepatitis B, C and D may lead to severe complications including chronic hepatitis, cirrhosis and hepatocellular carcinoma. The latest edition of Viral Hepatitis offers an essential resource of current information for hepatologists, gastroenterologists, infectious diseases specialists and other clinicians, researchers, public health physicians and National and International Health Authorities.




Chronic Viral Hepatitis


Book Description

Chronic viral hepatitis affect hundreds of millions of people worldwide, and each year millions more people become infected. In Chronic Viral Hepatitis, Second Edition, a panel of distinguished clinicians and clinical investigators build upon the first edition by comprehensively reviewing all the relevant new information regarding resistance, side effects, and therapies for chronic viral hepatitis. The text covers recent advances in the understanding of pathogenesis of viral hepatitis while discussing promising agents in development for its treatment. The authors devote special attention to reactivation of hepatitis B with chemotherapy and immunosuppression, herbal and non-traditional therapies, chronic viral hepatitis in the pediatric population, and immunology and immunotherapy of HCV and provide relative costs for all diagnostic and therapeutic options. Authoritative and up-to-date, Chronic Viral Hepatitis, Second Edition offers today's gastroenterologists, internists, hepatologists, and infectious disease specialists a practical guide to the recognition, diagnosis and treatment of chronic viral hepatitis from a multidisciplinary approach.




Recommendations and guidance on hepatitis C virus self-testing


Book Description

WHO has set a global goal to eliminate HCV as a public health problem by 2030. WHO estimates that 58 million people had chronic hepatitis C virus (HCV) infection globally in 2019, and less than a quarter of them were diagnosed. New and innovative approaches are needed to accelerate progress toward the HCV elimination targets. Self-testing is one such approach. These guidelines provide a new recommendation and guidance on HCV self-testing to complement existing HCV testing services in countries. These guidelines also highlight operational considerations to support strategic implementation and scale up of HCV self-testing.